Overview

A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations

Status:
Completed
Trial end date:
2015-08-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the multiple dose pharmacokinetics (PK) of two gefapixant (AF-219) formulations; to assess the effect of omeprazole on the multiple dose PK of two gefapixant formulations; and, to assess the safety and tolerability of gefapixant.
Phase:
Phase 1
Details
Lead Sponsor:
Afferent Pharmaceuticals, Inc.
Collaborator:
Celerion
Treatments:
Omeprazole